On June 15, Tempus AI rose 6.11% in regular trading, trading at $50.21/share, with turnover of $68.33 million. The stock rebounded strongly from its recent low of $47.12 recorded in the prior session, as bullish momentum accelerated on renewed optimism around the company's regulatory and product milestones.
On the news front, Tempus AI previously secured FDA approval for its tumor-specific xT CDx next-generation sequencing platform, making it the first laboratory to hold FDA companion diagnostic approvals for both tumor-specific and tumor-normal genomic profiling. The approval is expected to drive an approximately $200 increase in average selling price beginning in 2027. Additionally, the company recently launched Lens, a next-generation Agent AI platform designed for oncology drug development, and presented new multimodal oncology foundation model results at the ASCO annual meeting.
The rebound also follows notable selling pressure from major shareholder LEFKOFSKY ERIC P, whose sustained share disposals had weighed on the stock in recent sessions. The current move is viewed as a technical recovery after the stock pulled back from prior gains tied to the FDA catalyst.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments